MOUNTAIN VIEW, Calif., May 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations: Conference 2013 Annual Scientific Meeting of the American Society of Hypertension (ASH) May 15-18, 2013 San Francisco Marriott, San Francisco, CA Date / Time Oral Presentation Date: Saturday, May 18, 2013 at 8:30am Session Location: San Francisco Marriott, Yerba Buena Ballroom 9 Presentation Title Cardiovascular Effects Based on Magnitude of Weight Loss in Obese/Overweight Subjects With Hypertension Receiving Phentermine and Topiramate Extended-Release Authors: George Bakris, MD, FASH, FASN a; Michael H. Davidson, MD, FACC, FACP a; Alok K. Gupta, MD, FTOS, FASH, FAAFP b Affiliations: aASH Comprehensive Hypertension Center, The University of Chicago Pritzker School of Medicine, Chicago, IL; bClinical Research, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA Conference 166 th Annual Meeting of the American Psychiatric Association (APA) May 18-22, 2013 Moscone Center, San Francisco, CA Date / Time Poster Presentation Date: Monday, May 20, 2013 from 2:00pm-4:00pm Session Location: Moscone South Exhibit Hall A-C Poster Session: 9 Poster number: NR9-54 Presentation Title Weight Loss and Depression in Overweight/Obese Subjects With a History of Depression Receiving Phentermine and Topiramate Extended-Release Authors: Patrick M. O'Neil, PhD a; Craig A. Peterson, MS b Affiliations: aMedical University of South Carolina, Charleston, SC; bVIVUS, Inc., Mountain View, CA Conference 18 th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) May 18-22, 2013 Sheraton New Orleans, New Orleans, LA, USA Poster1 Date / Time Poster Presentation Date: Monday, May 20, 2013 from 3:45pm – 7:45 pm with discussion hour from 6:45pm-7:45pm Poster Session: II Poster Number: PSY13
Presentation TitleEffects of Phentermine and Topiramate Extended-Release Treatment on Weight Loss When Stratified by Baseline Body Mass Index Over 1 Year Author(s) Authors: Donna Ryan, MD a; Timothy Church, MD a; Sunil Karnawat b; Barbara Troupin, MD b Affiliations: aPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA bVIVUS, Inc., Mountain View, CA, USA Poster 2 Date / Time Poster Presentation Date: Monday, May 20, 2013 from 3:45pm – 7:45 pm with discussion hour from 6:45pm-7:45pm Poster Session: II Poster Number: PSY4 Presentation Title The Potential Cost Savings Associated With Preventing the Development of Hypertension, Diabetes, and Dyslipidemia in an Obese Population Author(s) Authors: Carlton R. a; Bramley T. a; Zagadailov E a.; Karnawat S. b Affiliations: aXcenda, Palm Harbor, FL; bVIVUS, Inc., Mountain View, CA About Qsymia Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established. Important Safety Information Qsymia ® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia. Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.About VIVUS VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com. Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc. Dana B. Shinbaum Corporate Development & Investor Relations firstname.lastname@example.org Investor Relations: The Trout Group Brian Korb email@example.com 646-378-2923